Vikas Gurjar

Vikas Gurjar

Auto-generated profile, based on publicly available information

Vikas Gurjar

ICMR-National Institute for Research in Environmental Health, India

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2024 in Microchemical Journal
Verified
Journal Article
Closed access
VGVikas Gurjar
Vikas Gurjar
NNNazim Nazeer
Nazim Nazeer
ABArpit Bhargava
Arpit Bhargava
NSNikita Soni
Nikita Soni
PKPrasan Kaur
Prasan Kaur
PMPradyumna Kumar Mishra
Pradyumna Kumar Mishra

19 April 2024
Verified
Book Chapter
Closed access
NNNazim Nazeer
Nazim Nazeer
PRPooja Ratre
Pooja Ratre
KZKaniz Zehra Zaidi
Kaniz Zehra Zaidi
VGVikas Gurjar
Vikas Gurjar
RDRakhi Dewangan
Rakhi Dewangan
Pradyumna Kumar MishraPradyumna Kumar Mishra
Pradyumna Kumar Mishra
In the realm of nanophotonics, there has been a noticeable increase in demand for semiconductor nanomaterials over the past few years. Quantum dots (QDs) have captured global scientific attention due to their unique optical properties. QDs comprise a semiconductor material core surrounded by a shell with a wider bandgap, which determines their optoelectrical properties. This chapter looks closely at various types of QDs, including carbon-based, perovskite, colloidal, magnetic QDs, and metal-based QDs. The authors examine different methods of surface functionalization and doping to optimize the performance of QDs. QDs have numerous applications in biomedical imaging and nanosensing. QDs are highly suitable as they demonstrate excellent photostability and bright emission, making them ideal for use as both fluorescent detectors and reporter molecules in laser scanning confocal microscopy, super-resolution microscopy, molecular spectroscopy, and flow cytometry. Request access from your librarian to read this chapter's full text.

17 November 2026 in bioRxiv
Verified
Preprint
Open access
SRShivam Rane
Shivam Rane
SMSoheel Mishra
Soheel Mishra
PCPhillip Carvalho
Phillip Carvalho
VGVikas Gurjar
Vikas Gurjar
RTRajnarayan R Tiwari
Rajnarayan R Tiwari
Pradyumna Kumar MishraPradyumna Kumar Mishra
Pradyumna Kumar Mishra
Circulating microRNAs (miRNAs) have potential as minimally invasive biomarkers for glioblastoma (GBM), but the small size of discovery groups makes it difficult to develop a classifier. The discovery cohort, GSE122488, comprised 38 patients (n = 38). Generative data augmentation was applied to increase the dataset, although evaluations based on held-out samples from the same cohort or a single validation set make it difficult to distinguish biological signals from cohort- or platform-specific effects. CTGAN and Tabular Variational Autoencoder (TVAE) models were trained on the 38-patient cohort producing 500 synthetic samples each. Random Forest and XGBoost classifiers were trained on augmented datasets and assessed using an escalating validation approach: first on an independent plasma cohort of the same modality (GSE184472, n = 118), and then on a tissue cohort from a different platform (Chinese Glioma Genome Atlas (CGGA), n = 198). XGBoost using TVAE-augmented data achieved an AUROC of 0.59 (95% CI 0.49-0.70) on GSE184472, compared with 0.42 to 0.53 without augmentation, although no AUROC on this cohort was significantly different from chance. However, this improvement did not carry to CGGA, where AUROC was 0.40 (95% CI 0.32-0.48) before harmonisation and 0.47 after Min-Max harmonisation. After harmonisation, a recall of 1.00 resulted from predicting every sample as GBM, leading to an accuracy of 0.41 and showing poor discrimination. The generalisation gap was examined in terms of modality mismatch, differing class definitions between cohorts, synthetic-data-related class imbalance, and incomplete cross-platform harmonisation. These findings show the need for independent, cross-platform validation before using data augmentation for diagnosis. The escalating validation framework provides a way to evaluate generalizability in small-cohort studies.